Anavex Life Sciences Corp (AVXL)

[falconer66a]

Now, Finally, Anavex 3-71 Comes Into Play

Of all of the positive news in today’s announcement, I found the following (for me, at least) to be the most significant.

This morning’s announcement stated:

ANAVEX®3-71 successfully completed IND-enabling toxicology studies and drug product manufacturing. ANAVEX®3-71 previously received Orphan Drug Designation from the U.S. FDA for Frontotemporal dementia (FTD). Initiation of the first Phase 1 clinical trial of ANAVEX®3-71 is expected in 2020. ANAVEX®3-71 has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.

As I’ve contended, the statement confirms that this new sigma-1 receptor agonist (Anavex 3-71) has been tested on transgenic mice with Alzheimer’s. In these little rodents it “has demonstrated disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, inflammation, amyloid and tau pathologies.”

That pretty much covers Alzheimer’s treatment, does it not? I won’t go into it here, but there is abundant evidence from murine testing that Anavex 3-71 is even better able to moderate and normalize various homeostatic processes. Simply, it will most likely turn out to be even better than blarcamesine (Anavex 2-73). Glad to learn that human trials are forthcoming.

From my start with my AVXL holding, I’ve targeted 2023 as the year in which I will determine my investment success. So far, I will hold to it. By 2023, remarkable things will have happened with blarcamesine; most likely it will have gained sales approval somewhere. In 2023, the clinical results with Anavex 3-71 could appear from humans with Alzheimer’s and frontotemporal dementia (FTD). No reason whatsoever to anticipate results will be lacking. Just the opposite; probably far better than even blarcamesine.